Alphatec Holdings, Inc. (ATEC) Stock Analysis
Range Bound setup
Healthcare · Medical Devices
Sell if holding. Momentum 2.1/10 is below the 5.0 floor at $10.29 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Leverage penalty (D/E 16.5): -1.5; Concentration risk — Supplier: Invibio.
Alphatec Holdings is a medical technology company focused exclusively on spine surgery, offering approach-specific procedures integrated with its InformatiX platform and EOS imaging technology. Revenue was $764.2 million for the year ended December 31, 2025, a 25% increase... Read more
Sell if holding. Momentum 2.1/10 is below the 5.0 floor at $10.29 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Leverage penalty (D/E 16.5): -1.5; Concentration risk — Supplier: Invibio. Chart setup: RSI 43 mid-range, Bollinger mid-band. Score 5.8/10, moderate confidence.
Passes 5/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA) and earnings proximity 4d<=7d. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHSupplierInvibio10-K Item 1A: 'We rely on a number of suppliers and in one case on a single source vendor, Invibio, to provide the raw materials used in the production of our products'
- MEDIUMProductpolyaxial pedicle screw systems38%10-K Item 1A: 'Net sales of our systems that include polyaxial pedicle screws represented approximately 38% and 40% our net sales for the years ended December 31, 2025 and 2024'
Material Events(8-K, last 90d)
- 2026-03-03Item 5.02LOWWard W. Woods retired from the Board effective February 27, 2026, for personal reasons, not due to any disagreement with the Company. A Vesting Acceleration Agreement was entered into for unvested RSUs.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers·2 ceiling hits
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Momentum 2.1/10 is below the 5.0 floor at $10.29 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Leverage penalty (D/E 16.5): -1.5; Concentration risk — Supplier: Invibio. Chart setup: RSI 43 mid-range, Bollinger mid-band. Prior stop was $9.57. Score 5.8/10, moderate confidence.
Take-profit target: $21.10 (+105.0% upside). Prior stop was $9.57. Stop-loss: $9.57.
Concentration risk — Supplier: Invibio; Leverage penalty (D/E 16.5): -1.5; Earnings in 4 days (event risk).
Alphatec Holdings, Inc. trades at a P/E of N/A (forward 17.0). TrendMatrix value score: 8.9/10. Verdict: Sell.
19 analysts cover ATEC with a consensus score of 4.1/5. Average price target: $24.
What does Alphatec Holdings, Inc. do?Alphatec Holdings is a medical technology company focused exclusively on spine surgery, offering approach-specific...
Alphatec Holdings is a medical technology company focused exclusively on spine surgery, offering approach-specific procedures integrated with its InformatiX platform and EOS imaging technology. Revenue was $764.2 million for the year ended December 31, 2025, a 25% increase year-over-year.